Expanding our global reach with new Lipid & LNP Starter Kit stock in Tokyo, Japan! As we recognize the importance of access to the supply of effective pharmaceutical-grade lipids with reduced order-to-delivery times, we are excited to announce the establishment of a new lipid stock in Tokyo, Japan. This strategic move provides enhanced proximity to a specially selected group of our highly pure standard lipids, including those proven to be effective in our new Lipid NanoParticle (LNP) Starter Kits, to our valued Asian and Japanese customers. For more information or to place an inquiry for our Japan stock of Lipids and LNP Starter Kits, click here: https://lnkd.in/ecByaKK7 #cordenpharma #cdmo #lipids #japan #lnps #lipidnanoparticles #pharmaceuticals #pharma #pharmaindustry #lnp #mrna #genetherapy
Corden Pharma - A Full-Service CDMO’s Post
More Relevant Posts
-
https://lnkd.in/g4dT_xg7 Key Insights: • Doxazosin tablets are prescribed for hypertension treatment, aimed at reducing blood pressure • The product will be available for commercial distribution from UniChem’s manufacturing facility located in Goa Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #unichem #approval #fdaapproval #bloodpressure #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights
To view or add a comment, sign in
-
The US Prefilled Syringes Market size was valued at USD 275 Bn. in 2023 and the total US Prefilled Syringes revenue is expected to grow at a CAGR of 11.2% from 2024 to 2030, reaching nearly USD 578.18 Bn. in 2030. The US prefilled syringes market is experiencing significant growth, driven by advancements in biologics, increased demand for self-administration of drugs, and the need for more efficient and safer drug delivery systems. Prefilled syringes offer numerous advantages, including reduced medication errors, improved patient compliance, and enhanced safety for healthcare providers. As healthcare continues to evolve, the role of prefilled syringes in streamlining processes and ensuring accurate dosing is becoming increasingly vital. Request for sample Report:https://lnkd.in/dBW2m7VU #HealthcareInnovation #PrefilledSyringes #PatientSafety #Pharmaceuticals #MedicalDevices
To view or add a comment, sign in
-
Dr. Mimoun Ayoub, Ph.D., Senior VP, Global Head of Sales & Key Account Management, discusses our broad CDMO capabilities to supply complex modalities such as small to large-scale peptides (including GLP-1s), lipids and oligos, as well as Lipid NanoParticle (LNP) formulation, sterile injectable drug products, and our extensive capacity of small molecule APIs & Drug Products, both highly potent and regular potency for Oral Solid Dosage. Learn more about our six technology platforms and how we support you in delivering complex modalities to your patients: https://lnkd.in/ejrr4frU #cordenpharma #cdmo #pharma #pharmaceuticals #drugdiscovery #drugdevelopment #pharmaceuticals #lipids #peptides #highlypotent #injectables #lnps
To view or add a comment, sign in
-
Top 200 Brand Name Drugs - 2023 Sales by Jon Njardarson and team just published on their website. The poster is freely available here - https://lnkd.in/dRVsaNfE Quick takeaways: -Keytruda continues as one of the top selling drugs over the last several years -Unabated rise of GLP-1 receptor antagonist -Biologics continue to break into the market
Top 200 Drugs 2023 #medicine Wanted to highlight the recent poster Jon Njardarson and team just published on their website. Top 200 Brand Name Drugs By 2023 Sales. Keytruda (Pembroluzimab) the best selling drug in 2023. 25 Billion in Sales. Ozempic (Semaglutide) now the 3rd best selling drug in 2023. Expect to see this go to top spot in 2024. The next decade to be dominated by the GLP-1 receptor agonists? The wonder drug. The poster is freely available here - https://lnkd.in/dRVsaNfE Also the Top 200 Small molecule drugs by 2023 sales here if you missed it. Great stuff - make sure to print out and stick on the wall in lab! #pharmaceuticals #healthcare
To view or add a comment, sign in
-
GLP analogs are key players in the drug market 2023
Top 200 Drugs 2023 #medicine Wanted to highlight the recent poster Jon Njardarson and team just published on their website. Top 200 Brand Name Drugs By 2023 Sales. Keytruda (Pembroluzimab) the best selling drug in 2023. 25 Billion in Sales. Ozempic (Semaglutide) now the 3rd best selling drug in 2023. Expect to see this go to top spot in 2024. The next decade to be dominated by the GLP-1 receptor agonists? The wonder drug. The poster is freely available here - https://lnkd.in/dRVsaNfE Also the Top 200 Small molecule drugs by 2023 sales here if you missed it. Great stuff - make sure to print out and stick on the wall in lab! #pharmaceuticals #healthcare
To view or add a comment, sign in
-
#Detox_Products Market Projections Indicate Moderate CAGR from 2023 to 2032 https://bit.ly/41xaQ4p #Detox products are #primarily used for #detoxification, the body's natural #process of getting rid of #toxins and unwanted #substances. By lowering the #levels of toxins in the #body while using #specific detox products to #support the detoxification #process, detox #products help #improve the body's #functions. MYLAN N.V. Mallinckrodt Pharmaceuticals Novartis Souvie Biodelivery Pfizer Daiichi Pharmaceutical Corp Teva Pharmaceuticals Ranbaxy VALEANT PHARMACEUTICALS INTERNATIONAL INC #pharmaceutical #technologies #detox #productdevelopment #healthcareindustry #healthcaremanagement
To view or add a comment, sign in
-
Acne Treatment Drug Market, Global Outlook and Forecast 2023-2030 || Download FREE Sample of this Report https://lnkd.in/dFmYfMuR The global Acne Treatment Drug market was valued at US$ 3721.3 million in 2022 and is projected to reach US$ 4656.3 million by 2029, at a CAGR of 3.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. by Company: Galderma Bausch Health Companies Inc. Teva Pharmaceuticals GSK Mylan Almirall SUN PHARMA Mayne Pharma Lion Huapont-Nutrichem Co., Ltd. Shanghai Bracco Sine Pharmaceutical Corp. Ltd. Get the Complete Report & TOC https://lnkd.in/dzdDktSx CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Follow Us On linkedin :- https://lnkd.in/d-gZVjNy #acnetreatment #acnetreatmentdrug #acne #pharmaceutical #acnetreatmentmarketreport #acnetreatmentmarketsize #acnetreatmentmarketgrowth #grandresearchstore
To view or add a comment, sign in
-
Top 200 Drugs 2023 #medicine Wanted to highlight the recent poster Jon Njardarson and team just published on their website. Top 200 Brand Name Drugs By 2023 Sales. Keytruda (Pembroluzimab) the best selling drug in 2023. 25 Billion in Sales. Ozempic (Semaglutide) now the 3rd best selling drug in 2023. Expect to see this go to top spot in 2024. The next decade to be dominated by the GLP-1 receptor agonists? The wonder drug. The poster is freely available here - https://lnkd.in/dRVsaNfE Also the Top 200 Small molecule drugs by 2023 sales here if you missed it. Great stuff - make sure to print out and stick on the wall in lab! #pharmaceuticals #healthcare
To view or add a comment, sign in
-
GSK has announced that US FDA has granted Fast track Designation for bepirovirsen ( an investigational triple action antisense oligonucleotide) for the treatment of chronic Hepatitis B. The Designation was granted on the basis of data from Ph2b trials B-Clear (https://bit.ly/3uvxeQc) and B-Sure (https://bit.ly/49czgnr) evaluating efficacy and safety of bepirovirsen in patients with Chronic hepatitis B. Bepirovirsen is a novel ASO candidate that originated from Ionis Pharmaceuticals’ research. In August 2019, GSK acquired the license to co-develop bepirovirsen with Ionis. It is currently being evaluated in Ph3 trials B-Well 1(https://bit.ly/3SBsv7p) and B-well 2 (https://bit.ly/3T0gmus) in Chronic Hepatitis B https://bit.ly/3uvvVAM Stay tuned for more updates #bepirovirsen #gsk #hepatitisb #oligonucleotide #oligonucleotides #fda #fasttrack #competitiveintelligence #pharma #pharmaceutical #biotech #productmarketing #healthcare #lifesciences #lifesciencesconsulting
To view or add a comment, sign in
-
🔬 Exciting New Pharmaceutical Products Available! 🔬 Looking for cutting-edge pharmaceutical products to enhance your research or drug development efforts? We have two remarkable offerings that are sure to grab your attention: Product 1: (R)-3-aminopiperidine dihydrochloride - CAS number: 334618-23-4 - Molecular formula: C5H14Cl2N2 - Molecular weight: 173.08 - Usage: This compound belongs to the family of synthetic dipeptidyl peptidase IV (DPP-IV) inhibitors. Known for their role in diabetes medications, DPP-IV inhibitors like Sitagliptin and Alogliptin are widely used to regulate blood sugar levels effectively. Product 2: - CAS number: 98977-36-7 - Molecular formula: C10H17NO3 These high-quality products hold immense potential for advancing your scientific endeavors. Whether you're conducting groundbreaking research or developing innovative pharmaceutical solutions, these compounds can be invaluable assets in your quest for success. Get in touch with us today to inquire about availability, pricing, and any additional information you may require. Our team of experts is ready to assist you in harnessing the power of these extraordinary compounds. Stay ahead of the curve and propel your scientific achievements to new heights with these remarkable additions to your laboratory! #Pharmaceuticals #Research #Innovation #Science #DrugDevelopment #DiabetesMedications
To view or add a comment, sign in
37,173 followers
Project Manager specialist presso A2A Illuminazione Pubblica
4moWhat impact do you anticipate the new availability of the Lipid & LNP Starter Kit in Tokyo will have on the research and development timelines for your Asian and Japanese customers?